問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2025-10-18

盧心玉
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

盧心玉

List

1Cases

2025-08-01 - 2032-12-31

Phase III

Active
AcTFirst: A phase III, open-label, multicenter, randomized trial comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration-resistant prostate cancer

  • Condition/Disease

    rPFS was defined as the time elapsed from the date of randomization to the date of the first documented radiographic disease progression or death from any cause as assessed by the Blinded Independent Central Review Committee (BICR) using conventional imaging and Prostate Cancer Working Group 3 (PCWG3) revised RECIST version 1.1 criteria, whichever occurred first.

  • Test Drug

    AAA617 AAA817 Abiraterone Cabazitaxel

Participate Sites
5Sites

Recruiting5Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB